Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Extending the rationale of combination therapy to unresponsive erectile dysfunction.

Literature DB >> 18231616

Extending the rationale of combination therapy to unresponsive erectile dysfunction.

Christopher Reece, Rajeev Kumar, Diedre Nienow, Ajay Nehra.

Abstract

Combination therapies aim to overcome the limitations of individual drugs by selecting diverse targets of action to enhance effectiveness synergistically. This article reviews the principles of combination therapy and its applications for benign prostatic hyperplasia and overactive bladder. It then examines pathophysiological, pharmacological, and clinical evidence for currently available drug and device combinations for erectile dysfunction that has not responded to first-line, single-agent therapy.

Entities: Disease

Keywords: Benign prostatic hyperplasia; Combination therapy; Erectile dysfunction; Intracavernosal therapy; Intraurethral therapy; Overactive bladder

Year: 2007 PMID： 18231616 PMCID： PMC2213890

Source DB: PubMed Journal: Rev Urol ISSN： 1523-6161

37 in total

1. Intracavernous injection of papaverine for erectile failure.

Authors: R Virag
Journal: Lancet Date: 1982-10-23 Impact factor: 79.321

2. Efficacy, safety, and use of sildenafil in urologic practice.

Authors: E Fagelman; A Fagelman; R Shabsigh
Journal: Urology Date: 2001-06 Impact factor: 2.649

Review 3. Combination treatment in hypertension: the VeraTran Study.

Authors: G Mancia; S Omboni; G Grassi
Journal: Am J Hypertens Date: 1997-07 Impact factor: 2.689

Review 4. Pharmacotherapeutic advances in the treatment of erectile dysfunction.

Authors: A Nehra; D M Barrett; R B Moreland
Journal: Mayo Clin Proc Date: 1999-07 Impact factor: 7.616

5. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy.

Authors: A Nehra; M L Blute; D M Barrett; R B Moreland
Journal: Int J Impot Res Date: 2002-02 Impact factor: 2.896

6. Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy.

Authors: J P Mulhall; M Daller; A M Traish; S Gupta; K Park; P Salimpour; T R Payton; R J Krane; I Goldstein
Journal: J Urol Date: 1997-11 Impact factor: 7.450

7. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction.

Authors: S A Kaplan; R B Reis; I J Kohn; R Shabsigh; A E Te
Journal: Urology Date: 1998-11 Impact factor: 2.649

8. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.

Authors: A Bechara; A Casabé; G Chéliz; S Romano; N Fredotovich
Journal: J Urol Date: 1996-03 Impact factor: 7.450

9. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.

Authors: W H Frishman; B S Bryzinski; L R Coulson; V L DeQuattro; N D Vlachakis; W J Mroczek; G Dukart; J D Goldberg; D Alemayehu; K Koury
Journal: Arch Intern Med Date: 1994-07-11

10. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.

Authors: O Shenfeld; J Hanani; A Shalhav; Y Vardi; B Goldwasser
Journal: J Urol Date: 1995-09 Impact factor: 7.450

4 in total

4. A study of the possible effects of repeated intracorporeal self-injection of vasoactive drugs in patients with elevated end diastolic velocity during pharmacopenile duplex ultrasonography.

Authors: Ashraf Hasan Fayez; Yasser El-Khayat; Hosam Hosny; Shady Zaki; Rany Shamloul
Journal: Cent European J Urol Date: 2013-08-13